

# Chronisch entzündliche Darmerkrankungen

## Grundlagen, Neues zur Diagnostik und Therapie

Birgit Terjung, Bonn

### Literaturverzeichnis

- Shivananda S, Lennard-Jones J, Logan R et al. (1996) Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). *Gut* 39: 690–697
- Henriksen M, Jahnsen J, Lygren I et al. (2006) Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSEN study). *Inflamm Bowel Dis* 12: 543–550
- Henriksen M, Jahnsen J, Lygren I et al. (2007) Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). *Scand J Gastroenterol* 42: 602–610
- Bonen DK, Cho JH (2003) The genetics of inflammatory bowel disease. *Gastroenterology* 124: 521–536
- Wehkamp J, Harder J, Weichenthal M et al. (2004) NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. *Gut* 53: 1658–1664
- Ogura Y, Bonen DK, Inohara N et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 411: 603–606
- Cho JH, Brant SR (2011) Recent insights in the genetics of inflammatory bowel diseases. *Gastroenterology* 140: 1704–1712
- Calkins BM (1989) A meta-analysis of the role of smoking in inflammatory bowel disease. *Dig Dis Sci* 34: 1841–1854
- Koletzko S, Uhlig HH (2010) Hygienehypothese: Schlüssel zur Ätiologie und Pathogenese der CED? *Monatsschr Kinderheilk* 158: 759–765
- Reddy A, Fried B (2009) An update on the use of helminths to treat Crohn's and other autoimmune diseases. *Parasitol Res* 104: 217–21
- Shih DQ, Targan SR (2009) Insights in IBD pathogenesis. *Curr Gastroenterol Rep* 11: 473–480
- Hoffmann JC, Zeitz M, Bischoff SC et al. (2004) S3-Leitlinie: Diagnostik und Therapie der Colitis ulcerosa. Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten zusammen mit dem Kompetenznetz chronisch entzündliche Darmerkrankungen. *Z Gastroenterol* 42: 979–1042
- Hoffmann JC, Preiss JC, Autschbach F et al. (2008) S3-Leitlinie Diagnostik und Therapie des Morbus Crohn: Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten zusammen mit dem Kompetenznetz chronisch entzündliche Darmerkrankungen. *Z Gastroenterol* 46: 1094–1146
- Dignass A, van Assche G, Lindsay JO et al. (2010) European Crohn's and Colitis Organisation (ECCO). The second European-evidence based consensus on the diagnosis and management of Crohn's disease: Current management. *J Crohn's and Colitis* 4: 28–62
- D'Haens G, Baert F, van Assche G et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet* 371: 660–667
- Colombel JF, Sandborn WJ, Reinisch W et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 362: 1383–1395
- Rutgeerts P, Vermeire S, van Assche P (2007) Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? *Gut* 56: 453–455
- Van Assche G, Vermeire S, Rutgeerts P (2010) Mucosal healing and anti-TNFs in IBD. *Curr Drug Targets* 11: 227–244
- Gasche C, Berstad A, Befrits R et al. (2007) Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. *Inflamm Bowel Dis* 13: 1545–1553